| Dr John Hugh Steely, MD | |
|
881 Uss James Madison Rd, Naval Submarine Base Kings Bay, Kings Bay, GA 31547-2531 | |
| (912) 573-8801 | |
| Not Available |
| Full Name | Dr John Hugh Steely |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 25 Years |
| Location | 881 Uss James Madison Rd, Kings Bay, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508814682 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 81560 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Two Zeds Medical Corporation | 7810291291 | 9 |
| Jurkowski Medical Corporation | 7911155304 | 10 |
News Archive
Biology researchers at Rutgers-Newark have identified a new link between a specific protein and its role in determining how cancerous cells divide, spread and form new tumors in other parts of the human body.
The Chronic Fatigue Initiative (CFI) - a new privately funded research directive focused on chronic fatigue syndrome - announced a substantial grant to a Columbia University research team to investigate the role of pathogens in causing chronic fatigue syndrome. The pathogen discovery and pathogenesis program will be led by Drs. Ian Lipkin and Mady Hornig of the Center for Infection and Immunity.
Melbourne researchers are urging women on Hormone Replacement Therapy (HRT) to be extra vigilant about having regular two-yearly mammograms.
The FDA today took legal action against a dietary supplement maker and owner for substituting ingredients and products without noting the changes on the final product labels. The permanent injunction, filed on behalf of the FDA by the U.S. Department of Justice, would stop the defendants from making and distributing more than 400 products for being in violation of the Federal Food, Drug, and Cosmetic Act.
Argos Therapeutics today announced two oral presentations detailing data on its soluble CD83 (sCD83) protein program at the 2010 American Transplant Congress, held May 1-5 in San Diego. The data, which were produced by Argos in collaboration with scientists from the University of Western Ontario, demonstrate that sCD83 is capable of inducing immune system tolerance to transplant grafts and suppressing an anti-donor antibody response, via a multi-faceted mechanism-of-action that impacts B and T cells, as well as dendritic cells.
› Verified 3 days ago
| Entity Name | Southern California Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770515280 PECOS PAC ID: 6002729175 Enrollment ID: O20031110000678 |
News Archive
Biology researchers at Rutgers-Newark have identified a new link between a specific protein and its role in determining how cancerous cells divide, spread and form new tumors in other parts of the human body.
The Chronic Fatigue Initiative (CFI) - a new privately funded research directive focused on chronic fatigue syndrome - announced a substantial grant to a Columbia University research team to investigate the role of pathogens in causing chronic fatigue syndrome. The pathogen discovery and pathogenesis program will be led by Drs. Ian Lipkin and Mady Hornig of the Center for Infection and Immunity.
Melbourne researchers are urging women on Hormone Replacement Therapy (HRT) to be extra vigilant about having regular two-yearly mammograms.
The FDA today took legal action against a dietary supplement maker and owner for substituting ingredients and products without noting the changes on the final product labels. The permanent injunction, filed on behalf of the FDA by the U.S. Department of Justice, would stop the defendants from making and distributing more than 400 products for being in violation of the Federal Food, Drug, and Cosmetic Act.
Argos Therapeutics today announced two oral presentations detailing data on its soluble CD83 (sCD83) protein program at the 2010 American Transplant Congress, held May 1-5 in San Diego. The data, which were produced by Argos in collaboration with scientists from the University of Western Ontario, demonstrate that sCD83 is capable of inducing immune system tolerance to transplant grafts and suppressing an anti-donor antibody response, via a multi-faceted mechanism-of-action that impacts B and T cells, as well as dendritic cells.
› Verified 3 days ago
| Entity Name | Jurkowski Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750644258 PECOS PAC ID: 7911155304 Enrollment ID: O20120910000256 |
News Archive
Biology researchers at Rutgers-Newark have identified a new link between a specific protein and its role in determining how cancerous cells divide, spread and form new tumors in other parts of the human body.
The Chronic Fatigue Initiative (CFI) - a new privately funded research directive focused on chronic fatigue syndrome - announced a substantial grant to a Columbia University research team to investigate the role of pathogens in causing chronic fatigue syndrome. The pathogen discovery and pathogenesis program will be led by Drs. Ian Lipkin and Mady Hornig of the Center for Infection and Immunity.
Melbourne researchers are urging women on Hormone Replacement Therapy (HRT) to be extra vigilant about having regular two-yearly mammograms.
The FDA today took legal action against a dietary supplement maker and owner for substituting ingredients and products without noting the changes on the final product labels. The permanent injunction, filed on behalf of the FDA by the U.S. Department of Justice, would stop the defendants from making and distributing more than 400 products for being in violation of the Federal Food, Drug, and Cosmetic Act.
Argos Therapeutics today announced two oral presentations detailing data on its soluble CD83 (sCD83) protein program at the 2010 American Transplant Congress, held May 1-5 in San Diego. The data, which were produced by Argos in collaboration with scientists from the University of Western Ontario, demonstrate that sCD83 is capable of inducing immune system tolerance to transplant grafts and suppressing an anti-donor antibody response, via a multi-faceted mechanism-of-action that impacts B and T cells, as well as dendritic cells.
› Verified 3 days ago
| Entity Name | Two Zeds Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275909434 PECOS PAC ID: 7810291291 Enrollment ID: O20160204001332 |
News Archive
Biology researchers at Rutgers-Newark have identified a new link between a specific protein and its role in determining how cancerous cells divide, spread and form new tumors in other parts of the human body.
The Chronic Fatigue Initiative (CFI) - a new privately funded research directive focused on chronic fatigue syndrome - announced a substantial grant to a Columbia University research team to investigate the role of pathogens in causing chronic fatigue syndrome. The pathogen discovery and pathogenesis program will be led by Drs. Ian Lipkin and Mady Hornig of the Center for Infection and Immunity.
Melbourne researchers are urging women on Hormone Replacement Therapy (HRT) to be extra vigilant about having regular two-yearly mammograms.
The FDA today took legal action against a dietary supplement maker and owner for substituting ingredients and products without noting the changes on the final product labels. The permanent injunction, filed on behalf of the FDA by the U.S. Department of Justice, would stop the defendants from making and distributing more than 400 products for being in violation of the Federal Food, Drug, and Cosmetic Act.
Argos Therapeutics today announced two oral presentations detailing data on its soluble CD83 (sCD83) protein program at the 2010 American Transplant Congress, held May 1-5 in San Diego. The data, which were produced by Argos in collaboration with scientists from the University of Western Ontario, demonstrate that sCD83 is capable of inducing immune system tolerance to transplant grafts and suppressing an anti-donor antibody response, via a multi-faceted mechanism-of-action that impacts B and T cells, as well as dendritic cells.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Hugh Steely, MD 881 Uss James Madison Rd, Naval Submarine Base Kings Bay, Kings Bay, GA 31547-2531 Ph: (912) 573-8801 | Dr John Hugh Steely, MD 881 Uss James Madison Rd, Naval Submarine Base Kings Bay, Kings Bay, GA 31547-2531 Ph: (912) 573-8801 |
News Archive
Biology researchers at Rutgers-Newark have identified a new link between a specific protein and its role in determining how cancerous cells divide, spread and form new tumors in other parts of the human body.
The Chronic Fatigue Initiative (CFI) - a new privately funded research directive focused on chronic fatigue syndrome - announced a substantial grant to a Columbia University research team to investigate the role of pathogens in causing chronic fatigue syndrome. The pathogen discovery and pathogenesis program will be led by Drs. Ian Lipkin and Mady Hornig of the Center for Infection and Immunity.
Melbourne researchers are urging women on Hormone Replacement Therapy (HRT) to be extra vigilant about having regular two-yearly mammograms.
The FDA today took legal action against a dietary supplement maker and owner for substituting ingredients and products without noting the changes on the final product labels. The permanent injunction, filed on behalf of the FDA by the U.S. Department of Justice, would stop the defendants from making and distributing more than 400 products for being in violation of the Federal Food, Drug, and Cosmetic Act.
Argos Therapeutics today announced two oral presentations detailing data on its soluble CD83 (sCD83) protein program at the 2010 American Transplant Congress, held May 1-5 in San Diego. The data, which were produced by Argos in collaboration with scientists from the University of Western Ontario, demonstrate that sCD83 is capable of inducing immune system tolerance to transplant grafts and suppressing an anti-donor antibody response, via a multi-faceted mechanism-of-action that impacts B and T cells, as well as dendritic cells.
› Verified 3 days ago
Kenneth Andrew Conrad, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 881 Uss James Madison Rd, Naval Branch Health Clinic, Kings Bay, GA 31547 Phone: 912-573-8801 |